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Abstract
Context and purpose: Organ exchange programmes are important in order to ensure organs to highly
immunized kidney patients. In this case report, we describe a highly immunized patient in an acceptable mismatch
program who had an unexpected positive Complement-Dependent Cytotoxicity (CDC) crossmatch with a deceased
donor exchange.
Main findings: Subsequent evaluation revealed donor specific antibodies characterized by serological epitopes,
which included the HLA-DQα chain, were masked in the standard IgG Luminex assay unless the serum was diluted;
however, the antibodies demonstrated high MFI values when the serum was pretreated with EDTA or analyzed with
the C1q assay. These findings led us to evaluate the extent of masked anti-HLA-DQ antibodies that included HLA-
DQα/DQβ pairs rather than just the HLA-DQβ chains in 16 highly immunized patients on the kidney transplantation
waiting list at our transplantation center. We determined that 25% of the patients had antibodies directed towards
serological epitopes that involved the anti-HLA-DQα chain but were masked in the standard IgG assay.
Principal conclusions: We conclude that masked anti-HLA-DQ antibodies directed towards serological epitopes
that also involves the HLA-DQα chain are common and should be considered as they may cause a positive CDC
crossmatch. Thus, donor specific HLA-DQ antibodies must be evaluated in relation to full HLA-DQα; DQβ pairs in
the serological molecules of the donor.
Keywords: HLA antibodies; Standard IgG single antigen bead assay;
EDTA; C1q assay; Prozone effect
Abbreviations: CDC: Complement-Dependent Cytotoxicity; cPRA:
Calculated Panel Reactive Antibodies; EDTA:
Ethylenediaminetetraacetic Acid; FXM: Flow-Cytometric Crossmatch;
HI: Highly Immunized; HLA: Human Leukocyte Antibodies; MFI:
Mean Fluorescence Intensity; PBS: Phosphate-Buffered Saline; PCR-
SSP: Polymerase Chain Reaction with Sequence-Specific Primer; PRA:
Panel Reactive Antibodies; SAB: Single Antigen Bead; STAMP:
Scandiatransplant Acceptable Mismatch Programme.
Introduction
Donor specific human leukocyte antigen (HLA) alloantibodies
(DSA) are risk factors for the development of rejection and decreased
graft survival in kidney transplantation [1]. Highly sensitized kidney
patients have a lower chance of receiving a donor kidney offer than
other patients on waiting lists [2], which has motivated many
transplantation centers to introduce special programs [2,3]. The basis
of acceptable mismatch programs is the determination of unacceptable
HLA antigen mismatches. Most programs consider only highly
expressed HLA antigens encoded by HLA-A; B;DRB1, though this is
supplemented by HLA-DQB1 in some centers [2,4]. The standard IgG
Luminex single antigen bead (SAB) assay is widely used to tailor
acceptable antigens for future organ offers. This approach is reasonable
as Luminex assays are considered to be at least as sensitive as the
cellular based flow cytometric crossmatch (FXM) method and are
much more sensitive than a crossmatch based on complement-
dependent cytotoxicity (CDC) in antibody detection. However, the
Luminex assays have revealed that transplanted patients frequently
develop de novo antibodies directed against serological epitopes that
involve lowly expressed HLA chains, such as HLA-DQα and -DPβ,
which is associated with poor graft prognosis [1] and challenging
future transplantations. Additionally, a proportion of patient’s exhibit
inhibitory effects in their serum, leading to falsely reduced mean
fluorescence intensity (MFI) levels in the IgG SAB assays, which is
referred to as the prozone effect [5-7].
Case
A 51-year-old highly immunized (HI) man with terminal kidney
failure secondary to hypertension was accepted in the
Scandiatransplant acceptable mismatch program (STAMP) [2] for HI
patients in September 2014. He received an organ offer in February
2015 with an unexpected positive B-cell crossmatch in a CDC-based
assay as HLA-A;B;C, DRB1 and DQB1 mismatches were all among the
predefined acceptable antigens based on the analyses performed using
a Luminex SAB assay (One Lambda Inc., Canoga/Los Angeles, CA). A
positive B-cell crossmatch in the CDC-based assay is considered to be
a contraindication for transplantation at our transplantation center,
which is in line with international consensus guidelines [8]. The
patient was temporarily inactivated in the STAMP, but remained on
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the local kidney transplantation waiting list during the review of his
medical and immunological records.
Medical history: At the time of enrollment in the STAMP, the
patient had a medical history of hemodialysis initiated in 1994 and
previous kidney transplantation in July 1995 with a deceased donor.
Due to a failing kidney graft, peritoneal dialysis was started in
September 2010, and the patient was re-enrolled on the kidney waiting
list in July 2011. When he entered the STAMP in September 2014, he
had been on the waiting list for 38 months.
Immunology: The patient was HLA-A*03,*68; B*35,*38; C*04,*12;
DRB1*08:01P,*13:01; DQA1*01:03,*03:01; DQB1*03:02,*06:03. Hospital
records showed that the first graft in 1995 had introduced antigen
mismatches at HLA-A1; B7,8; DR2,3; and DQ1. At the time of
enrollment in the STAMP, the patient was HI, which is defined as
having panel reactive antibodies (PRA)>80% in a CDC assay with
DTT treated serum tested against a panel of B lymphocytes.
Acceptable mismatches were defined by negative reactions
(MFI<1000) in the Luminex SAB assay (One Lambda Inc., Canoga/Los
Angeles, CA). Based on these analyses, the calculated PRA (cPRA) was
32% for HLA class I and 53% for HLA class II when the calculator
provided by the HLA Fusion™ 2.0 software (version 3.3, One Lambda
Inc., Canoga/Los Angeles, CA) was used against 1751 Danish donors
as an approximation of the background population. The combined
HLA class I and class II cPRA was 90% when a calculator provided by
the Scandiatransplant database was used. None of these calculators
considered antibodies directed against HLA-DQA1, DPA1 or DPB1.
The patient had no antibodies directed against HLA-DP. Anti-HLA-
DQα antibodies were not considered to be a transplantation barrier as
they were in linkage disequilibrium with HLA-DQB1 antigens that had
already been excluded as acceptable antigens.
The organ offer from a deceased donor in the STAMP in February
2015 introduced HLA-A*02,*32; B*40:01,*44; C*03:02,*05; DRB1*11;
DQB1*03:01 mismatches that were all among the predefined
acceptable mismatches. The CDC crossmatch was highly positive
against the donor B-cells but not against the donor T cells. Both
analyses included DTT treated serum. HLA typing of the donor was
confirmed at our center with real time PCR (LinkSeq, Linkage
Bioscience, CA, US). Autoantibodies were excluded. We found that the
patient reacted with an MFI>1000 for two out of five beads with HLA-
DQB1*03:01 antigens in combination with HLA-DQA1*05:05 or HLA-
DQA1*06:01 but not in combination with HLA-DQA1*02:01,*03:01, or
*05:03. Among Caucasians, the HLA-DRB1*11; DQB1*03:01 haplotype
is in linkage disequilibrium with HLA-DQA1*05 (http://
www.allelefrequencies.net/hla6003a.asp).
The donor was typed to be HLA-DQA1*05:05 by polymerase chain
reaction with sequence-specific primer (PCR-SSP) (Olerup SSP AB,
Stockholm, Sweden). We investigated whether donor specific
antibodies had been masked in the standard IgG Luminex bead assays,
which were extended to include dilutions of serum and EDTA treated
serum. Additionally, the LABScreen C1q SAB assay (One Lambda Inc.,
Canoga/Los Angeles, CA) was used with diluted and undiluted serum
to evaluate complement binding. We found no additional anti-HLA-A,
-Cw, -DRB1*, -DRB3*, -DRB4*, -DRB5*, -DQB1* or -DP antibodies in
these analyses. However, in the EDTA-treated sample, three additional
anti-HLA-B antibodies were detected, though none of them were
donor-specific and thus were unlikely to cause the positive B-cell
crossmatch. Moreover, we found anti-HLA-DQA1*05:05 antibodies
with increasing MFI values in the diluted, EDTA-treated serum using
the IgG assay as well as the C1q assay (Figure 1).
Figure 1. Detection of anti-HLA-DQA1*05:05 antibodies in our
reported case with different pretreatments of the patient serum. In
the standard IgG Luminex assay, the antibody was found to have a
low MFI of <1500, whereas dilution of the sera led to an unexpected
increase in the MFI value to >10,000. Additional EDTA-treatment
and evaluation with the C1q assay revealed increasing MFI values of
>20,000, thus explaining the unexpected positive CDC B-cell
crossmatch in this patient. All testing was performed on the same
sera. All dilutions were 1:8 in PBS.
Similar patterns were found for anti-HLA-DQA1*05:01 and anti-
HLA-DQA1*05:03. Beads with HLA-DQB1*03:01 antigens remained
negative in combination with HLA-DQA1*02:01 and HLA-
DQA1*03:01 in all additional assays. Accordingly, we concluded that
the positive B-cell crossmatch was most likely caused by complement
binding/activating of the patient antibodies directed against serological
epitopes that were encoded by HLA-DQA1*05:05 alone or the HLA-
DQA1*05:05;DQB1*03:01 pair. We performed additional dilution of a
new serum and found an increase in the MFI value even when diluted
1:100 (data not shown). Thus, we found masked antibodies using the
standard IgG Luminex SAB assay due to a prozone phenomenon
caused by complement interference as they were unmasked after
dilution or when EDTA treatment was used. Moreover, these
antibodies were detected with the C1q assay, both in undiluted and 1:8
diluted sera, supporting that they had a high titer in addition to being
complement binding.
Follow-up: In May 2016, the patient was re-enrolled in the STAMP
with an exclusion of HLA-DQB1*03:01 due to its linkage equilibrium
to the HLA-DQA1*05 encoded α-chain. In July 2016, he received a
kidney offer from a deceased donor with the following mismatches:
HLA-A*02,*11; B*15; C*03:02;*03:03 and DRB1*04. The donor was a
complete match for the HLA-DQα and -DQβ loci. The CDC B-cell
crossmatch was negative, and the patient was transplanted.
To date, nine months after transplantation the graft is well-
functioning without any diagnosed rejection episodes. The patient is
normotensive without edema on 100 mg metoprolol and 20 mg
furosemide. Plasma-creatinine has stabilized to approximately 180-200
μmol/l and the glomerular filtration rate has been estimated to 40 ml/
min, which is clinically satisfying for a transplanted kidney patient.
Renal arterial resistance index was estimated at 0.7 at follow-up four
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months after transplantation that is within the normal range.
Additionally, the patient has a leukocyte count, plasma-calcium and
plasma-phosphate within the normal range.
Figure 2. All the false-negative anti-HLA-DQα antibodies in the
standard IgG Luminex assay among our highly immunized patients
on the kidney transplantation waiting list. False-negative reactions
were defined as an MFI value below our cut-off MFI of 1000 in the
standard IgG Luminex assay and an MFI value above the cut-off
after 1:8 dilution of serum in the standard IgG Luminex assay. A
total of nine antibody specificities in four of the 16 patients were
identified. The figure shows these results in both diluted and EDTA-
treated sera in the IgG assay and the results from the C1q assay with
both undiluted and diluted sera. The antibody specificities include:
anti-HLA-DQA1*01:03, -DQA1*03:02, -DQA1*05:01, -
DQA1*05:03, -DQA1*05:05 and -DQA1*06:01. For each patient, all
testing was performed on the same sera. All dilutions were 1:8 in
PBS.
The interference of inhibitory factors in serum on the detection of
antibodies directed towards HLA-DQα/β epitopes.
Because of this case, we examined the extent of masked antibodies
directed towards serological epitopes involving HLA-DQα chains alone
or HLA-DQα/β pairs in 16 HI kidney patients on the waiting list using
the standard IgG single antigen assay. HI was defined as having
PRA>80% in a CDC-based screening against a B-cell panel. We
performed testing with regular, 1:8 diluted and EDTA-treated patient
sera in conjunction with testing using the C1q assay with regular and
1:8 diluted patient sera.
A total of four patients (25%) with nine antibody specificities,
including our index patient, exhibited inhibition/prozone phenomena
in the detection of antibodies directed towards epitopes on serological
HLA-DQα/β molecules. Inhibition was defined as an MFI<1000 in
undiluted serum and more than double MFI in 1:8 diluted serum in
the standard assay (Figure 2), and were thus classified as false-negative
reactions for the standard Luminex IgG assay. All of these antibodies
were detected after the addition of EDTA and in the C1q assay, both in
undiluted and diluted serum, with MFI values above 20000, which may
result in a positive CDC B-cell crossmatch, as occurred in the reported
case.
Figure 3. All of the false-negative reactions of the standard IgG
Luminex assay among our highly immunized patients on the kidney
transplantation waiting list. False-negative reactions were defined as
an MFI value below our cut-off MFI of 1000 in the standard IgG
Luminex assay and an MFI value above the cut-off after 1:8 dilution
of serum in the standard IgG Luminex assay. A total of 16 antibody
specificities in five of the 16 patients were identified. All 16 antibody
specificities were diagnosed in the EDTA-treated sera and in the
C1q assay with MFI values >20,000 which could result in a positive
CDC B-cell crossmatch. The antibody specificities included anti-
HLA-A1, -A23, -A24, -A31, -B50, and -B57 on HLA class I; two
antibody specificities were targeted against previously known
mismatches. For HLA class II, we found only false-negative
reactions for the anti-HLA-DQα antibodies, including anti-HLA-
DQA1*01:03, -DQA1*03:02, DQA1*05:01, -DQA1*05:03, -
DQA1*05:05 and -DQA1*06:01. For each patient, all testing was
performed on the same sera. All dilutions are 1:8 in PBS.
Our review was extended to include all identified anti-HLA
antibodies, which revealed false-negative reactions in the standard IgG
Luminex assay for a total of 16 antibody specificities among five
patients (31%), including seven HLA-A and –B specificities and nine
anti-HLA-DQα antibodies (Figure 3) of which two (13%) had false-
negative reactions corresponding to one or more previously identified
HLA mismatches.
We observed a tendency of higher MFI values in diluted sera (1:8)
compared to undiluted sera in the C1q assay (Figure 3), suggesting that
prozone phenomena may occur in the C1q assay as well as in the IgG
assay, although no false negative reactions were observed in the C1q
assay.
Discussion
In this case report, we found that antibodies directed towards
serological HLA-DQ epitopes that involved the HLA-DQA1*05:05
encoded α-chain alone or the HLA-DQα,β pair caused a positive CDC
B-cell crossmatch in an HI kidney patient. These antibodies had a very
Citation: Lund KP, Hauge AW, Sørensen SS, Bruunsgaard H (2017) Case Report: Anti-HLA-DQα Antibodies Have Clinical Impacts in Highly
Immunized Kidney Patients. J Clin Cell Immunol 8: 498. doi:10.4172/2155-9899.1000498
Page 3 of 4
J Clin Cell Immunol, an open access journal
ISSN:2155-9899
Volume 8 • Issue 2 • 1000498
high MFI value in diluted, EDTA-treated sera and in the C1q assay, but
they had a low MFI value in the standard IgG Luminex single antigen
assay most likely due to complement interference, as the dissociation
or destruction of complement C1 by EDTA treatment eliminated the
effect as previously described [6,7]. There do not exist reports that
address the importance of such antibodies in CDC crossmatching in
the pre-transplantation setting as the HLA-DQα chains is not
evaluated in most clinical settings. One report described a patient who
developed anti-HLA-DQα antibodies post-transplantation [9] and two
cases reported unexpected positive B-cell FXM due to donor specific
anti-HLA-DQα antibodies in living donor kidney transplantations
[10,11]. This case underlines both 1) the possible clinical significance
of antibodies directed towards serological epitopes that involves the
HLA-DQA1 encoded α-chain in the HLA-DQ molecule in the pre-
transplantation setting and 2) the common occurrence of masking of
such antibodies in HI kidney recipients.
The majority of de novo DSA are directed against HLA class II
antigens, especially serologically defined HLA-DQ antigens mainly
defined by HLA-DQB1, as reviewed by Filippone et al. [1]. This
approach may result in an underreported incidence of antibodies
directed towards epitopes that involve the HLA-DQα chain as well,
and thus an underestimation of the clinical consequence of these
antibodies, when previously transplanted patients undergo future
transplantation [12,13]. The antibody reactions in our patient
correspond to the DQA 41GR eplet and our findings support that the
current nomenclature system does not reflect the true nature of HLA-
DQ polymorphisms as concluded by Tambur et al. [14]. Currently, the
typing of HLA-DQα chains in donors and the reporting of anti-HLA-
DQα antibodies in recipients are not mandatory in many clinical
programs such as STAMP in our center, although our case
demonstrates the potential problems of positive crossmatching [12].
Another concern is the interpretation of HLA-DQ antibodies when
DQα- and DQβ-chains are paired on beads, which may block the DQα
epitopes of the molecule, reducing the significance of their
contribution [13]. We found false-negative antibodies directed towards
epitopes that involved the HLA-DQA1encoded α-chain in 25% of the
HI patients in our cohort. We suggest that the clinical consequences of
these antibodies are underestimated and prospective HLA-DQA1
typing combined with HLA-DQB1 of kidney donors should be
performed when antibodies directed towards HLA-DQ molecules are
evaluated. Moreover, acceptable HLA mismatches have previously
often been solely based on findings from the standard IgG SAB assay
for highly immunized patients but we found that 31% had false-
negative reactions due to the effect of inhibitory factors in serum and
that 13% had false-negative reactions corresponding to one or more
previously identified HLA mismatch in our HI patients.
Conclusion
We report that antibodies directed towards epitopes that involve the
HLA-DQA1 chain in HI patients are common but often overlooked,
which may result in a positive CDC B-cell crossmatch as these
antibodies often bind C1q according to our investigation. Additionally,
we conclude that donor specific HLA-DQ antibodies must be
evaluated in relation to full HLA-DQα; DQβ pairs in the serological
molecules of the donor.
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